Space News: 50 years ago, NASA sent 2 spacecraft to search for life on Mars – the Viking missions’ findings are still discussed today Lake County News,California Source link
Read More »Tag Archives: Viking
50 years ago, NASA sent 2 spacecraft to search for life on Mars – the Viking missions’ findings are still discussed today
This article was originally published at The Conversation. The publication contributed the article to Space.com’s Expert Voices: Op-Ed & Insights. Finding life beyond the Earth would be a major scientific discovery with significant implications for all areas of science and human thought. Yet, only one direct search for extraterrestrial life has ever been conducted. The NASA Viking spacecraft, which landed …
Read More »50 years ago, NASA sent 2 spacecraft to search for life on Mars – the Viking missions’ findings are still discussed today
Finding life beyond the Earth would be a major scientific discovery with significant implications for all areas of science and human thought. Yet, only one direct search for extraterrestrial life has ever been conducted. The Viking missions landed on the Martian surface using parachutes. This diagram shows each stage the spacecraft went through as they landed. NASA The NASA Viking …
Read More »Viking Therapeutics oral weight loss drug hits mark in mid-stage trial
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. A new oral weight loss drug developed by Viking Therapeutics hit the mark in a mid-stage clinical trial, but the …
Read More »Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40% – Bloomberg
Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40% Bloomberg Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate Yahoo Finance Viking Therapeutics shares fall 40% on disappointing obesity pill trial data CNBC High drop-out rate clouds weight loss data for Viking’s oral drug FirstWord Pharma This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and …
Read More »Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
Key Takeaways Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill. Overall, 28% of those taking VK2735 left the Phase 2 trial early compared with 18% among placebo subjects. The research showed the pill reduced the weight of patients who took it for 13 weeks by up to 26.7 pounds. Viking …
Read More »Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More Movers – Barron's
Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More Movers Barron’s Stocks making the biggest moves premarket: Intel, Palo Alto Networks, Best Buy and more CNBC 5 Things to Know Before the Stock Market Opens Investopedia Stocks to Watch Recap: Intel, Medtronic, Home Depot, Rocket Lab The Wall Street Journal Stock Movers: Home Depot, Intel, Nvidia Bloomberg Source link
Read More »Viking Therapeutics loses a third of its value after oral weight-loss drug trial – MarketWatch
Viking Therapeutics loses a third of its value after oral weight-loss drug trial MarketWatch Viking Therapeutics shares fall 40% on disappointing obesity pill trial data CNBC Viking Therapeutics (VKTX) Stock Fell More Than 30%. What Sent It Crashing. Barron’s Viking’s oral pill reduces up to 12.2% weight but shares slump on higher patient exits Reuters Viking Therapeutics Rises as Phase 3 Trials and Oral …
Read More »Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
Investing.com — Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking’s oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary …
Read More »Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe …
Read More »